Short-term oral rapamycin prevents age-related learning impairment in mice
Haoyi Lei1, Juan Wang1, Warren Ladiges1
1Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, USA.
Abstract:
Effective treatments to prevent or delay age-related learning impairment are not generally available. In a preliminary preclinical study, mice 20 months of age were fed a diet containing 14 ppm rapamycin, an inhibitor of mTOR, for three months and then tested in a spatial navigation task. Mice fed the nonmedicated control diet showed learning impairment while mice fed the rapamycin diet were not learning impaired. This observation provides support for additional preclinical studies and suggests that short-term rapamycin treatment could be a possible strategy for preventing or delaying age-related cognitive impairment in people.
Insights
Short-term rapamycin treatment prevented age-related learning impairment in mice. This preclinical study suggests rapamycin may be a potential strategy to delay cognitive decline in humans.
Area of Science:
- Neuroscience
- Aging Research
- Pharmacology
Background:
- Age-related cognitive impairment is a significant concern with limited effective preventative treatments.
- The mechanistic target of rapamycin (mTOR) pathway is implicated in aging and cognitive function.
Purpose of the Study:
- To investigate the potential of rapamycin, an mTOR inhibitor, in preventing age-related learning impairment.
- To assess the effects of short-term rapamycin treatment on cognitive performance in aged mice.
Main Methods:
- A preclinical study involving 20-month-old mice.
- Mice were fed a diet containing 14 ppm rapamycin or a control diet for three months.
- Cognitive function was assessed using a spatial navigation task.
Main Results:
- Mice fed the control diet exhibited significant learning impairment.
- Mice treated with rapamycin did not show learning impairment.
- Rapamycin treatment appeared to preserve spatial navigation abilities in aged mice.
Conclusions:
- Short-term rapamycin administration may prevent or delay age-related learning deficits.
- These findings support further preclinical investigation of rapamycin for cognitive health.
- Rapamycin presents a potential therapeutic strategy for mitigating age-related cognitive decline.
More Related Videos
07:07Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
09:06Stereotactic Injection of MicroRNA-expressing Lentiviruses to the Mouse Hippocampus CA1 Region and Assessment of the Behavioral Outcome
Published on: June 10, 2013